Five minutes with…Börge Seeger, Neuwerk

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Five minutes with…Börge Seeger, Neuwerk

Börge Seeger - portrait (8).jpg

Börge Seeger reveals the similarities between IP strategy and F1, and opines on bookshops, espresso machines, and late-night emails

Welcome to the latest instalment of Managing IP’s ‘Five minutes with’ series, where we learn more about IP practitioners on a personal as well as a professional level. This time we have Börge Seeger, partner at Neuwerk in Germany.

Someone asks you at a party what you do for a living. What do you say?

I usually say something like: ‘I help life science companies do amazing things with their IP – getting drugs and diagnostics to market, building partnerships, making deals happen.’

If they’re still with me, I add: ‘It’s part law, part strategy, part translator between science and business.’

If they’ve already wandered off to the bar, I just say I’m a lawyer. Works either way.

Talk us through a typical working day.

Coffee. Inbox. Calls. Drafts. Repeat. No two days are the same, which I love. I might be negotiating a licensing agreement with a US biotech in the morning, reviewing a collaboration deal with a university hospital at noon, and advising a client on IP strategy for AI-powered diagnostics in the afternoon.

Plus, a few late-night WhatsApps with clients who just had an idea.

What are you working on at the moment?

A few pretty exciting things: A cross-border licensing and equity deal for a biotech client, a major out-licensing project involving an mRNA platform, and helping a pharma company restructure its global supply arrangements. And, on the side, getting bio.law (our online legal hub for the life sciences sector) ready for its next content wave.

Does one big piece of work usually take priority or are you juggling multiple things?

Always juggling – and mostly loving it. But when there’s a pivotal negotiation or a critical milestone, it tends to dominate everything else. The trick is to know when to focus hard and when to multitask like a maniac.

What is the most exciting aspect of your role, and what is the most stressful?

Exciting: Being right there when something new and bold gets off the ground – a first-in-class therapy, a breakthrough platform, a deal that opens new markets. Stressful: The just-one-more-turn-of-the-agreement emails at 11:47pm the night before signing.

Tell us the key characteristics that make a successful IP lawyer/practitioner.

Curiosity (you have to want to understand the tech). Clarity (translating science and strategy into something contractual). And resilience – IP law isn’t for the faint-hearted.

What is the most common misconception about IP?

That it’s just ‘legal protection’ or ‘something you register.’ It’s not. It’s often the entire value of the business. Getting IP strategy wrong is like putting bad fuel in a Formula 1 car.

What or who inspires you?

People who build things that matter. Young founders who bootstrap their science to clinical proof-of-concept. Nobel-prize-worthy researchers who stay curious. Clients who think big and get it done.

If you weren’t in IP, what would you be doing?

I’d probably run a bar somewhere sunny. Ideally, with a bookshop next door. Or maybe work in tech policy – I’m fascinated by the digital-health-AI-regulatory crossroads. Or both. Can you be a bartender/lawyer/philosopher?

Any advice you would give your younger self?

Take the call. Say yes to Stanford. Don’t worry too much – and always write that follow-up email.

What is your motto in life?

“Don’t overthink it – do the thing.” Also: “Smart, not fancy.” Applies to contracts, people, and espresso machines.

more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article